Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SL8T
|
|||
| Former ID |
DPR000177
|
|||
| Drug Name |
ISIS-FGFR4
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 2 | [1] | |
| Company |
ISIS Pharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | FGFR4 messenger RNA (FGFR4 mRNA) | Target Info | . | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | FGF signaling pathway | |||
| Pathway Interaction Database | FGF signaling pathway | |||
| Reactome | PI3K Cascade | |||
| PIP3 activates AKT signaling | ||||
| FGFR4 ligand binding and activation | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Phospholipase C-mediated cascade | ||||
| FRS-mediated FGFR4 signaling | ||||
| SHC-mediated cascade:FGFR4 | ||||
| PI-3K cascade:FGFR4 | ||||
| Negative regulation of FGFR4 signaling | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | ||||
| PIP3 activates AKT signaling | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02476019) A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients. | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.